Search - tctmd.com

Displaying 1 - 20 of 613

Sort: Relevancy | Date

Loberamisal Scores a Rare Win for Stroke Neuroprotection

News Conference News ISC 2026

Loberamisal Scores a Rare Win for Stroke Neuroprotection

February 12, 2026

Side Effects of Statins Might Be Overstated: CTT Collaboration

News Daily News

Side Effects of Statins Might Be Overstated: CTT Collaboration

Michael O'Riordan

February 12, 2026

OCEANIC-STROKE: Asundexian Prevents Recurrent Strokes, With No Added Bleeding

News Conference News ISC 2026

OCEANIC-STROKE: Asundexian Prevents Recurrent Strokes, With No Added Bleeding

February 09, 2026

Oral GLP-1s Provide Benefit in HF Patients: SOUL Subanalysis

News Daily News

Oral GLP-1s Provide Benefit in HF Patients: SOUL Subanalysis

February 06, 2026

FASTEST Hints at Benefits of Hemostatic Therapy for Acute ICH in Select Groups

News Conference News ISC 2026

FASTEST Hints at Benefits of Hemostatic Therapy for Acute ICH in Select Groups

February 05, 2026

Cardiologists Lack Resources to Help Hospitalized Patients Quit Smoking

News Daily News

Cardiologists Lack Resources to Help Hospitalized Patients Quit Smoking

January 08, 2026

Statins Work for Primary Prevention Even in Low-risk Patients With Type 2 Diabetes

News Daily News

Statins Work for Primary Prevention Even in Low-risk Patients With Type 2 Diabetes

January 05, 2026

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

News Daily News

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Michael O'Riordan

December 30, 2025

Andexanet Alfa Pulled From US Market

News Daily News

Andexanet Alfa Pulled From US Market

December 22, 2025

Aprocitentan Effective in CKD Patients With Resistant Hypertension: PRECISION

News Daily News

Aprocitentan Effective in CKD Patients With Resistant Hypertension: PRECISION

December 16, 2025

WHO Endorses Treating Obesity in Adults With GLP-1s

News Daily News

WHO Endorses Treating Obesity in Adults With GLP-1s

December 01, 2025

Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids

News Conference News AHA 2025

Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids

Michael O'Riordan

November 10, 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

News Conference News AHA 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Michael O'Riordan

November 08, 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

News Conference News AHA 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

November 08, 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

November 03, 2025

News Industry News

SMT’s Supraflex Cruz Shows Consistent and Robust Clinical Outcomes Across Key Global Studies Presented at TCT 2025

October 29, 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

News Conference News TCT 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

October 27, 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

News Conference News TCT 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

Michael O'Riordan

October 26, 2025

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

News Daily News

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

October 22, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.